体内动员及诱导骨髓干细胞治疗大鼠糖尿病的疗效

 目的联合应用表皮生长因子（EGF）与促肝细胞生长因子（pHGF）体内诱导动员后的自体骨髓干细胞，探讨能否使其转分化为胰岛素分泌细胞，观察该方法对链脲佐菌素（STZ）大鼠糖尿病的治疗作用。方法40 只SD大鼠随机分为对照组、糖尿病组、动员组及诱导组，每组10 只，后3 组均用STZ 制做糖尿病大鼠模型，成模后动员组和诱导组皮下注射重组人粒细胞集落刺激因子10 μg·kg^-1·d^-1，连续15 d，对照组和糖尿病组注射生理盐水。诱导组于动员第2 日腹腔注射EGF 1 μg·kg^-1·d^-1、pHGF0.3 mg·kg^-1·d^-1，连续14 d；其他3 组注射生理盐水对照。监测大鼠血糖、胰岛素水平，实验结束时免疫组化染色并计算胰腺中胰岛素阳性细胞百分比。结果治疗后诱导组大鼠血糖明显低于糖尿病组及动员组（P < 0.05），血清胰岛素明显高于另外2 组（P < 0.05），胰腺中胰岛素阳性细胞百分比明显高于另外2 组（ P< 0.01）。结论EGF 联合pHGF 体内可诱导动员后自体骨髓干细胞转分化为胰岛素分泌细胞，可以增加血浆胰岛素水平，降低血糖，治疗大鼠糖尿病。

Therapeutic Effects of In Vivo Mobilizing and Inducing Bone Marrow Stem Cells on Diabetes of Rats

Objective To explore the possibility of mobilized bone marrow stem cells(BMSCs) induced by epidermal growth factor(EGF)and hepatocyte growth-promoting factor(pHGF) in vivo differentiating into insulin-producing cells and to test the therapeutic potency of insulin-producing cells(IPCs) on diabetes of rats.Methods 40 SD rats were randomly divided into four groups which were normal control group,untreated diabetes group,mobilization group and induction group with 10 rats in each group.Rats in the latter three ...